These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies. Hoffmann MJ, Müller M, Engers R, Schulz WA. Biochem Pharmacol; 2006 Nov 30; 72(11):1577-88. PubMed ID: 16854382 [Abstract] [Full Text] [Related]
4. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, Fischette MR, Adnani MT, Loukinov DI, Vatolin S, Risinger JI, Custer M, Chen GA, Zhao M, Nguyen DM, Barrett JC, Lobanenkov VV, Schrump DS. Cancer Res; 2005 Sep 01; 65(17):7763-74. PubMed ID: 16140944 [Abstract] [Full Text] [Related]
5. Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. Loukinov D, Ghochikyan A, Mkrtichyan M, Ichim TE, Lobanenkov VV, Cribbs DH, Agadjanyan MG. J Cell Biochem; 2006 Aug 01; 98(5):1037-43. PubMed ID: 16741971 [Abstract] [Full Text] [Related]
6. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. Hoivik EA, Kusonmano K, Halle MK, Berg A, Wik E, Werner HM, Petersen K, Oyan AM, Kalland KH, Krakstad C, Trovik J, Widschwendter M, Salvesen HB. Oncotarget; 2014 Feb 28; 5(4):1052-61. PubMed ID: 24658009 [Abstract] [Full Text] [Related]
7. Hypomethylation of BORIS is a promising prognostic biomarker in hepatocellular carcinoma. He J, Huang Y, Liu Z, Zhao R, Liu Q, Wei L, Yu X, Li B, Qin Y. Gene; 2017 Sep 20; 629():29-34. PubMed ID: 28764977 [Abstract] [Full Text] [Related]
8. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K, Karpf AR. Cancer Immun; 2007 Dec 21; 7():21. PubMed ID: 18095639 [Abstract] [Full Text] [Related]
13. The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Klenova EM, Morse HC, Ohlsson R, Lobanenkov VV. Semin Cancer Biol; 2002 Oct 21; 12(5):399-414. PubMed ID: 12191639 [Abstract] [Full Text] [Related]
14. BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas. Hines WC, Bazarov AV, Mukhopadhyay R, Yaswen P. PLoS One; 2010 Mar 17; 5(3):e9738. PubMed ID: 20305816 [Abstract] [Full Text] [Related]
15. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. Tada Y, Brena RM, Hackanson B, Morrison C, Otterson GA, Plass C. J Natl Cancer Inst; 2006 Mar 15; 98(6):396-406. PubMed ID: 16537832 [Abstract] [Full Text] [Related]
16. Transcriptional silencing of hedgehog-interacting protein by CpG hypermethylation and chromatic structure in human gastrointestinal cancer. Taniguchi H, Yamamoto H, Akutsu N, Nosho K, Adachi Y, Imai K, Shinomura Y. J Pathol; 2007 Oct 15; 213(2):131-9. PubMed ID: 17724792 [Abstract] [Full Text] [Related]
18. Differential expression of the embryo/cancer gene ECSA(DPPA2), the cancer/testis gene BORIS and the pluripotency structural gene OCT4, in human preimplantation development. Monk M, Hitchins M, Hawes S. Mol Hum Reprod; 2008 Jun 15; 14(6):347-55. PubMed ID: 18467432 [Abstract] [Full Text] [Related]
19. BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer. Link PA, Zhang W, Odunsi K, Karpf AR. Cancer Immun; 2013 Jun 15; 13():6. PubMed ID: 23390377 [Abstract] [Full Text] [Related]